[go: up one dir, main page]

MX2024000006A - Proteinas de fusion inmunomoduladoras y sus usos. - Google Patents

Proteinas de fusion inmunomoduladoras y sus usos.

Info

Publication number
MX2024000006A
MX2024000006A MX2024000006A MX2024000006A MX2024000006A MX 2024000006 A MX2024000006 A MX 2024000006A MX 2024000006 A MX2024000006 A MX 2024000006A MX 2024000006 A MX2024000006 A MX 2024000006A MX 2024000006 A MX2024000006 A MX 2024000006A
Authority
MX
Mexico
Prior art keywords
fusion proteins
immunomodulatory fusion
relates
cell
immunomodulatory
Prior art date
Application number
MX2024000006A
Other languages
English (en)
Inventor
Philip D Greenberg
Shannon K Oda
Thomas M Schmitt
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of MX2024000006A publication Critical patent/MX2024000006A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción se relaciona con proteínas de fusión inmunomoduladoras que contienen un dominio de unión extracelular y un dominio de señalización intracelular, en el que la unión de un blanco puede generar una señal moduladora en una célula hospedera, tal como una célula T. La presente descripción también se relaciona con usos de células inmunes que expresan tales proteínas de fusión inmunomoduladoras para tratar ciertas enfermedades, tales como cáncer o una enfermedad infecciosa.
MX2024000006A 2017-03-17 2019-09-11 Proteinas de fusion inmunomoduladoras y sus usos. MX2024000006A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762473282P 2017-03-17 2017-03-17
US201862629663P 2018-02-12 2018-02-12

Publications (1)

Publication Number Publication Date
MX2024000006A true MX2024000006A (es) 2024-02-20

Family

ID=61911694

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010812A MX2019010812A (es) 2017-03-17 2018-03-16 Proteinas de fusion inmunomoduladoras y sus usos.
MX2024000006A MX2024000006A (es) 2017-03-17 2019-09-11 Proteinas de fusion inmunomoduladoras y sus usos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019010812A MX2019010812A (es) 2017-03-17 2018-03-16 Proteinas de fusion inmunomoduladoras y sus usos.

Country Status (8)

Country Link
US (2) US11725210B2 (es)
EP (1) EP3595706A1 (es)
JP (3) JP2020511136A (es)
CN (2) CN119409836A (es)
AU (1) AU2018236461B2 (es)
CA (1) CA3055784A1 (es)
MX (2) MX2019010812A (es)
WO (1) WO2018170475A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141357A1 (en) 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
WO2018119114A1 (en) 2016-12-22 2018-06-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018170168A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
JP2020511136A (ja) 2017-03-17 2020-04-16 フレッド ハッチンソン キャンサー リサーチ センター 免疫調節性融合タンパク質およびその使用
KR20200064085A (ko) 2017-09-07 2020-06-05 큐 바이오파마, 인크. 접합 부위를 갖는 t-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
CA3111384A1 (en) * 2018-09-05 2020-03-12 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
EP3856769A4 (en) * 2018-09-28 2022-08-17 Memorial Sloan Kettering Cancer Center IMMUNOREACTIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF
GB2569692A (en) * 2018-10-30 2019-06-26 Tc Biopharm Ltd T cell antigen receptor chimera
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2020132368A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
CA3129263A1 (en) * 2019-02-08 2020-08-13 Dna Twopointo Inc. Transposon-based modifications of immune cells
AU2020315796A1 (en) * 2019-07-19 2022-02-24 Memorial Hospital For Cancer And Allied Diseases Fusion polypeptide for immunotherapy
JP2022547866A (ja) * 2019-09-05 2022-11-16 ポセイダ セラピューティクス，インコーポレイティド 同種異系細胞組成物と使用方法
AU2020348502A1 (en) * 2019-09-16 2022-04-07 Mcmaster University Chimeric costimulatory receptors and methods and uses thereof
CN110790842B (zh) * 2019-11-25 2021-03-30 贵州康钦承平生物科技有限公司 一种FasL-CAR融合蛋白和表达融合蛋白的T细胞及其制备方法和应用
EP4087594A4 (en) * 2020-01-06 2024-02-28 Memorial Sloan Kettering Cancer Center Novel dominant negative fas polypeptides, cells comprising thereof and uses thereof
EP4118107A1 (en) * 2020-03-11 2023-01-18 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
EP4132962A1 (en) 2020-04-09 2023-02-15 Autolus Limited Molecule
CA3174812A1 (en) * 2020-04-09 2021-10-14 Autolus Limited Cell
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
CN116096405A (zh) 2020-05-12 2023-05-09 Cue生物制药股份有限公司 多聚体t细胞调节多肽及其使用方法
CN117844761A (zh) * 2020-05-22 2024-04-09 重庆精准生物技术有限公司 逆转肿瘤微环境的融合蛋白及其应用
CN116348485A (zh) 2020-07-17 2023-06-27 英研生物(英国)有限公司 提供用于过继性细胞疗法的靶向共刺激的受体
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
US11945876B2 (en) 2021-06-16 2024-04-02 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
WO2023288278A1 (en) 2021-07-16 2023-01-19 Instil Bio (Uk) Limited Chimeric molecules providing targeted costimulation for adoptive cell therapy
CN113621077B (zh) * 2021-09-02 2023-01-31 山东大学 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞
WO2023094527A1 (en) * 2021-11-25 2023-06-01 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Cd95 polypeptides
WO2023150801A2 (en) * 2022-02-07 2023-08-10 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding
WO2023192895A1 (en) * 2022-03-29 2023-10-05 Allogene Therapeutics Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
TW202402798A (zh) * 2022-05-23 2024-01-16 美商艾費尼Ｔ醫療公司 對新抗原具特異性之結合蛋白與工程化細胞及其用途
EP4293040A1 (en) 2022-06-19 2023-12-20 ETH Zurich Cell line for engineering cytokine receptors
WO2024046468A1 (en) * 2022-09-02 2024-03-07 Nanjing Legend Biotech Co., Ltd. Fusion proteins targeting lysosomal degradation pathway
KR20240095012A (ko) * 2022-11-29 2024-06-25 (주) 테라베스트 Cd137 세포외 도메인을 포함하는 융합단백질, 이를 발현하는 면역세포 및 이의 용도
CN121152813A (zh) * 2023-03-23 2025-12-16 恺兴生命科技(上海)有限公司 细胞免疫疗法的组合物和方法
WO2025006795A1 (en) * 2023-06-30 2025-01-02 Board Of Regents, The University Of Texas System Tsyn-seq: a t cell synapse-based tumor antigen identification platform
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
WO2025117773A2 (en) * 2023-11-30 2025-06-05 Affini-T Therapeutics, Inc. Compositions and methods for treating neoplasia
EP4599843A1 (en) 2024-02-09 2025-08-13 Fundació Institut de recerca de l'Hospital de la Santa Creu i Sant Pau Car and modified cd200r combination
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1999A (en) 1841-03-12 Improvement in seed-planters
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
PT737207E (pt) 1994-01-11 2005-02-28 Dyax Corp Inibidores de plasmina humana derivados de dominios kunitz
EP0787188A1 (en) 1994-11-01 1997-08-06 Targeted Genetics Corporation Chimeric receptors for the generation of selectively-activatable t h?-independent cytotoxic t cells
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
AU2006204459B2 (en) 2005-01-05 2012-11-01 F-Star Therapeutics Limited Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
WO2009040338A1 (en) 2007-09-24 2009-04-02 University Of Zürich Designed armadillo repeat proteins
WO2012012695A2 (en) 2010-07-23 2012-01-26 Fred Hutchinson Cancer Research Center A method for the treatment of obesity
WO2012042480A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN106074601A (zh) 2011-03-23 2016-11-09 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
MX380522B (es) 2011-04-08 2025-03-12 Baylor College Medicine Inversion de los efectos del micro-ambiente de tumor utilizando receptores de citocina quimericos.
ES2888651T3 (es) 2011-07-29 2022-01-05 Univ Pennsylvania Receptores de conmutación coestimulantes
US9688740B2 (en) 2011-10-26 2017-06-27 National Cancer Center Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2013192294A1 (en) * 2012-06-20 2013-12-27 Boston 3T Biotechnologies, Inc. Cellular therapies for treating and preventing cancers and other immune system disorders
CN105026424A (zh) 2013-01-01 2015-11-04 卡尔医疗有限公司 稳定形式的信号转化蛋白融合蛋白、及其使用和制备的方法
WO2014110591A1 (en) 2013-01-14 2014-07-17 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
CN103965361B (zh) 2013-02-06 2018-10-30 上海细胞治疗工程技术研究中心集团有限公司 一种t细胞信号的嵌合分子转换器及其用途
WO2014172584A1 (en) 2013-04-17 2014-10-23 Baylor College Of Medicine IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER
EP3172237A2 (en) 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using humanized anti-bcma chimeric antigen receptor
BR112017001242A2 (pt) 2014-07-21 2017-12-05 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico a cd33
TWI718992B (zh) 2014-07-21 2021-02-21 瑞士商諾華公司 使用cll-1嵌合抗原受體治療癌症
WO2016022400A1 (en) 2014-08-04 2016-02-11 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
LT3180363T (lt) 2014-08-15 2019-11-25 Merck Patent Gmbh Sirp-alfa imunoglobulino sulieti baltymai
HRP20240357T1 (hr) 2014-12-24 2024-06-07 Autolus Limited Stanica
WO2016118780A1 (en) 2015-01-21 2016-07-28 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
WO2016141357A1 (en) 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
ES2976647T3 (es) 2015-06-19 2024-08-06 Sebastian Kobold Proteínas de fusión PD-1-CD28 y su uso en medicina
ES2862907T3 (es) 2015-11-27 2021-10-08 Cartherics Pty Ltd Células genéticamente modificadas y usos de las mismas
US11026969B2 (en) 2015-12-23 2021-06-08 Fred Hutchinson Cancer Research Center High affinity T cell receptors and uses thereof
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
ES2981274T3 (es) * 2016-04-20 2024-10-08 Fred Hutchinson Cancer Center Proteínas de fusión de IL2R inmunomoduladoras y usos de las mismas
JP2020511136A (ja) 2017-03-17 2020-04-16 フレッド ハッチンソン キャンサー リサーチ センター 免疫調節性融合タンパク質およびその使用
WO2019061012A1 (zh) 2017-09-26 2019-04-04 南京凯地生物科技有限公司 靶向cd47的特异性嵌合抗原受体t细胞的制备及其应用
CN110330567B (zh) 2019-07-02 2020-11-06 南京凯地生物科技有限公司 双特异性嵌合抗原受体t细胞，其制备方法和应用

Also Published As

Publication number Publication date
CN119409836A (zh) 2025-02-11
US20200009190A1 (en) 2020-01-09
US20240218379A1 (en) 2024-07-04
AU2018236461B2 (en) 2025-03-27
CN110621335B (zh) 2025-06-03
US11725210B2 (en) 2023-08-15
JP2022113880A (ja) 2022-08-04
US12365906B2 (en) 2025-07-22
AU2018236461A1 (en) 2019-09-19
EP3595706A1 (en) 2020-01-22
WO2018170475A1 (en) 2018-09-20
JP2020511136A (ja) 2020-04-16
CA3055784A1 (en) 2018-09-20
MX2019010812A (es) 2019-12-11
JP2024019732A (ja) 2024-02-09
CN110621335A (zh) 2019-12-27
JP7465306B2 (ja) 2024-04-10

Similar Documents

Publication Publication Date Title
MX2024000006A (es) Proteinas de fusion inmunomoduladoras y sus usos.
MX2022006004A (es) Proteinas de fusion inmunomoduladoras y usos de las mismas.
MX2019001458A (es) Polipeptidos modificados y usos de los mismos.
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
MX2017008875A (es) Anticuerpos biespecificos contra cd3 y cd20.
BR112018012707A2 (pt) inibidores da interação de menin-mll
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
MX2018015252A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2022006513A (es) Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica.
MX2019008359A (es) Cadena j modificada.
MX2023004479A (es) Sistema de vector multiple y sus usos.
UY38003A (es) Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
WO2014116846A3 (en) Methods and compositions for modulating an immune response
MX2015013590A (es) Sistemas y metodos para la produccion dirigids de una proteina terapeutica dentro de una celula objetivo.
TWD170353S (zh) 項鍊
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
MX2018000278A (es) Terapia de receptores quimericos de puntos de control inmunitarios.
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
PE20151774A1 (es) Construcciones de proteinas mitocondriales y sus usos
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
MX390494B (es) UNA NUEVA SUBPOBLACIÓN DE TREGS CD8+CD45RCbajo Y SUS USOS.
MX2016013631A (es) Celulas huespedes modificadas y usos de las mismas.
MX377780B (es) Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.
CL2016002142A1 (es) Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas